Interestingly, using a combination therapy targeting IL13Rα2 and HER2 by bispecific CAR-T cells co-expressing IL13Rα2 and HER2 CAR molecules demonstrated significant potential for eliminating solid tumor cells and showed less antigen escape compared with mono-specific or pooled HER2-CAR-T and IL13Rα2-CAR-T cells alone in a glioblastoma model [91]. This evidence concerns the gene ERBB2 and glioblastoma.